ANDA Approvals Strong Again; Has FDA Turned The Corner?
This article was originally published in The Pink Sheet Daily
Executive Summary
After posting its two highest approval totals for fiscal year, Office of Generic Drugs’ review system finally may be shifting into high gear.
You may also be interested in...
GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table
Generic user fees could be segmented further by addition of new group.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.